Last reviewed · How we verify
Prevention of Disseminated Candidiasis — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Mycamine | MICAFUNGIN | Teva Pharms Usa Inc | Echinocandin Antifungal | ATP-binding cassette sub-family G member 2 | 2005-01-01 | |
| Diflucan | fluconazole | Pfizer Inc. | Azole Antifungal [EPC] | Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase | 1990-01-29 | |
| Fluconazol | Fluconazol | Azienda Sanitaria-Universitaria Integrata di Udine | Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Azienda Sanitaria-Universitaria Integrata di Udine · 1 drug in Prevention of Disseminated Candidiasis
- Pfizer Inc. · 1 drug in Prevention of Disseminated Candidiasis
- Teva Pharms Usa Inc · 1 drug in Prevention of Disseminated Candidiasis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Prevention of Disseminated Candidiasis:
- Prevention of Disseminated Candidiasis treatment updates — RSS
- Prevention of Disseminated Candidiasis treatment updates — Atom
- Prevention of Disseminated Candidiasis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Prevention of Disseminated Candidiasis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-disseminated-candidiasis. Accessed 2026-06-10.
Related
- Prevention of Disseminated Candidiasis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing